Reducing Costs And Improving Adherence For Self-Administration Of New Biologics

Many of the newer biologic products being developed are for long-term administration in chronic disease conditions, including oncology, autoimmune disorders and high cholesterol. Historically, these biologics have been administered by costly intravenous (IV) injection in a hospital, clinic or doctor’s office. IV administration has been used due to the higher dosing requirements – upwards of 100 mg. To help improve patient compliance and lower the cost of therapy, some of these products have been reformulated down to 1 mL or below. At this volume they can be self-administered using an auto-injector for the 1 mL long pre-filled syringe.